Results 81 to 90 of about 3,179,450 (287)

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.

PLoS ONE, 2020
Pancreatic cancer is an aggressive, solid tumor, with a grave prognosis. Despite surgical treatment in patients with pancreatic cancer, the rate of recurrence is high.
Yasunori Uesato, Naoki Sasahira, Masato Ozaka, Takashi Sasaki, Mitsuhisa Takatsuki, Hitoshi Zembutsu   +5 more
doaj   +1 more source

Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers

Frontiers in Digital Health, 2020
Improving cancer survival rates globally requires improvements in disease detection and monitoring, with the aim of improving early diagnosis and prediction of disease relapse. Traditional means of detecting and monitoring cancers rely largely on imaging
Mark R. Openshaw, Terri P. McVeigh
doaj   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Liquid Biopsy-Derived Tumor Biomarkers for Clinical Applications in Glioblastoma

Biomolecules
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid growth and resistance to chemotherapy. Conventional treatments remain largely ineffective, with patient survival averaging around 18 months after diagnosis ...
Bruna Pereira de Lima, Leticia Silva Ferraz, Sylvie Devalle, Helena Lobo Borges   +3 more
doaj   +1 more source

Circulating tumor DNA in early‐stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?

EMBO Molecular Medicine, 2015
The availability of blood‐based markers to predict response of a solid tumor to treatment, estimate patient prognosis and diagnose relapse well before clinical symptoms arise, is a long‐standing hope in clinical oncology.
Taija M af Hällström, Maija Puhka, Olli Kallioniemi   +2 more
doaj   +1 more source

Profiling neoadjuvant therapy response in rectal cancer using meta‐analysis of publicly available transcriptomic RNA‐seq datasets

Molecular Oncology, EarlyView.
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic, Rafael Stroggilos, Mladen Marinkovic, Ana Djuric, Suzana Stojanovic‐Rundic, Radmila Jankovic, Sergi Castellvi‐Bel, Remond J.A. Fijneman, Antonia Vlahou, Jerome Zoidakis, Milena Cavic   +10 more
wiley   +1 more source

Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma

JCO Precision Oncology, 2018
Purpose To evaluate the feasibility of using circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for the management of uveal melanoma (UM). Patients and Methods Low-coverage whole-genome sequencing was used to determine somatic chromosomal copy number alterations (SCNAs) in primary UM tumors, ctDNA, and whole-genome amplified CTCs.
Beasley, Aaron, Isaacs, Timothy, Khattak, Muhammad K., Freeman, James B., Allcock, Richard, Chen, Fred K., Pereira, Michelle R., Yau, Kyle, Bentel, Jaqueline, Vermeulen, Tersia, Calapre, Leslie, Millward, Michael, Ziman, Melanie R., Gray, Elin S.   +13 more
openaire   +3 more sources

Circulating tumor DNA – from biology to potential clinical applications in diffuse large B-cell lymphomas

During the last 20 years, significant progress has been made in understanding the biology of cancer cells. Assessment of the molecular profile of neoplastic cells collected by tissue biopsy using next-generation sequencing techniques makes it possible to
Kinga Gwóźdź-Bąk, Krzysztof Lewandowski   +1 more
core   +1 more source